Whole abdominal radiotherapy following cytoreductive surgery and chemotherapy in ovarian carcinoma

C. Ronald Kersh, Marcus E. Randall, William C. Constable, Seung S. Hahn, Peyton T. Taylor, Hans B. Krebs, Dean R. Goplerud

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Persistent or recurrent disease following surgery and chemotherapy in ovarian carcinoma remains a major therapeutic dilemma. Between January 1980 and December 1985, there were 26 patients who had previously undergone cytoreductive surgery and chemotherapy and were treated with external beam radiotherapy. Twenty-one of these patients had been treated with platinum-adriamycin-cytoxan (PAC) regimen and 5 were treated with other combinations. Surgical reevaluation was performed in 21 of the 26 patients and only 4 21 (19%) patients were free of disease. All 26 patients were irradiated with a planned dose of 2500 cGy/100 cGy/day or 2280 cGy/120 cGy/day to the whole abdomen and a final calculated dose to the pelvis of 4500 cGy. Initial evaluation showed a 3-year actuarial survival rate of 51% and a disease-free survival rate of 42%. Follow-up analysis yields survivals of 45 and 35%, respectively. Severe gastrointestinal complications were observed in 3 26 patients and all hematologic complications resolved. Variables of prognostic significance were chemotherapy tolerance, grade, and volume of residual disease. We conclude that a proportion of patients with disease following cytoreductive surgery and chemotherapy may be salvaged with abdominopelvic irradiation.

Original languageEnglish
Pages (from-to)113-120
Number of pages8
JournalGynecologic Oncology
Issue number1
StatePublished - Sep 1988

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Whole abdominal radiotherapy following cytoreductive surgery and chemotherapy in ovarian carcinoma'. Together they form a unique fingerprint.

Cite this